Warning: Common Pain Relievers Unsafe for Heart Patients
Fortunately, there are alternatives for those needing daily pain relief.
The FDA mandated a cardiovascular safety trial of celecoxib (Celebrex®). This trial, spearheaded by Dr. Nissen, compared moderate doses of celecoxib to ibuprofen and naproxenin 24,081 arthritis patients at increased cardiovascular risk needing daily pain relief. The cardiovascular risks from celecoxib were no greater than those conferred by the other NSAIDs.